Market Analysis
-
GRI Bio Won Orphan Drug Status the Same Day MAIA Opened a Third Cancer Trial Site
GRI Bio’s stock is down 94% over the past year. On June 18, the FDA handed it seven years of potential market exclusivity. The same day, across the industry, a different small-cap was quietly opening its third US trial site for a lung cancer drug nobody outside biotech circles has heard of. Regulatory wins and…
-
Uranium’s Return: Why One of the World’s Most Misunderstood Commodities Is Becoming Critical to the Future of Energy
For decades, uranium has been associated almost exclusively with nuclear weapons, Cold War politics, and catastrophic accidents such as Chernobyl and Fukushima. Yet that perception overlooks uranium’s far more significant role today. Far from being a military commodity, uranium has become an essential fuel for one of the world’s most reliable sources of clean electricity.…
-
Deep Fission Filed for an IPO and the SMR Sector Keeps Outpacing Its Own Reactors
Donald Trump and Iranian President Masoud Pezeshkian signed a memorandum of understanding to end a four-month war on June 17. By this morning, US crude had fallen below $75 a barrel for the first time since March, down to roughly $74, after Treasury Secretary Scott Bessent announced a 60-day sanctions waiver on Iranian oil sales.…
-
Kevin Warsh’s First Fed Meeting Gave Crypto Nothing and the Market Noticed
There is a kind of financial product whose entire selling point is that it does not do anything interesting. A preferred stock priced at $100 par, paying a steady dividend, designed to sit there and throw off income while the people who bought it go about their lives. On June 18, one of these instruments…
-
OpenAI Burned $3.7 Billion in Q1 and Filed for a $1 Trillion IPO in the Same Week
OpenAI made $5.7 billion in the first quarter of 2026. It spent $3.7 billion of that. Both numbers tripled year on year. The company then filed confidentially for an IPO that a source told Reuters could value it at up to $1 trillion. There is a version of this story where the revenue growth curve…
-
Auvelity FDA Approval Launches the First Non-Antipsychotic Market for Alzheimer Agitation
Roughly 39 million people live with HIV. Most of them are on treatment. A large proportion of those people are aging, developing comorbidities, accumulating drug resistance, and managing the complexity of multi-tablet regimens that have kept the virus suppressed but come with their own set of problems. Gilead Sciences has a drug in FDA review…
-
Section 45Y Wind Solar Construction Deadline Is 19 Days Away: What Developers Must Do
Coal powered the world for a hundred years. Built cities, ran railways, kept the lights on through two world wars. Last year, for the first time in modern history, it generated less electricity than renewables. The transition happened so gradually and then so completely that when the Ember Global Electricity Review published the numbers this…










